BeiGene, Ltd.
BGNEDrugs in Pipeline
48
Phase 3 Programs
26
Upcoming Catalysts
5
Next Catalyst
Jun 30, 2026
10wMarket Overview
Stock performance and key metrics
5 upcoming, 0 past
Sorafenib
Hepatocellular Carcinoma (HCC)
Pamiparib capsule
Ovarian Cancer
Gemcitabine Hydrochloride
Urothelial Carcinoma
bendamustine
Mantle Cell Lymphoma; Non-Hodgkin Lymphoma
Docetaxel
Non-small Cell Lung Cancer
Sonrotoclax
Chronic Lymphocytic Leukemia
Cisplatin
Esophageal Squamous Cell Carcinoma (ESCC)
Irinotecan
Esophageal Squamous Cell Carcinoma (ESCC)
Gemcitabine
Recurrent or Metastatic Nasopharyngeal Cancer
Etoposide
Small Cell Lung Cancer
Ibrutinib
Chronic Lymphocytic Leukemia
Fluorouracil (5-FU)
Esophageal Squamous Cell Carcinoma (ESCC)
Lenalidomide
Relapsed/Refractory Follicular Lymphoma
Venetoclax
Chronic Lymphocytic Leukemia
Pembrolizumab
Non-small Cell Lung Cancer
Carboplatin
Non-Small Cell Lung Cancer
Tislelizumab
Urothelial Carcinoma
Oxaliplatin
Gastric, or Gastroesophageal Junction Adenocarcinoma
Paclitaxel
Non-Small Cell Lung Cancer
BGB-3111
Waldenström's Macroglobulinemia
Ociperlimab
Limited Stage Small Cell Lung Cancer
Cisplatin injection
Non Small Cell Lung Cancer
Obinutuzumab
Relapsed/Refractory Follicular Non-Hodgkin Lymphoma
BGB-16673
Chronic Lymphocytic Leukemia
Zanubrutinib
Refractory Mantle Cell Lymphoma
5-fluorouracil
Resectable Esophageal Squamous Cell Carcinoma
Zanidatamab
Breast Cancer
Pemetrexed
Non Small Cell Lung Cancer
Capecitabine
Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
Tislelizumab (BGB-A317)
MSI-H/dMMR Solid Tumors
BGB-10188
Chronic Lymphocytic Leukemia
BGB-A445
Non-Small Cell Lung Cancer
Azacitidine
Acute Myeloid Leukemia
BGB-A425
Locally Advanced or Metastatic Solid Tumors for Phase 1,Dose Escalation and Phase 2 Safety Lead-in, HNSCC, NSCLC and RCC Participants for Phase 2
lenvatinib
Advanced Solid Tumor
5-FU
Esophageal Squamous Cell Carcinoma, Gastric Carcinoma, Gastroesophageal Junction Carcinoma
Supportive Care
COVID-19 Pulmonary Complications
BGB-11417
Mantle Cell Lymphoma
Chemotherapy Doublet
Esophageal Cancer
Fruquintinib
Advanced Solid Tumors
Pamiparib
Brain and Central Nervous System Tumors
Nab paclitaxel
Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC)
BGB-45035
Rheumatoid Arthritis
BGB-DXP593
Covid19
BGB-290
HER2-negative Breast Cancer
BAT1706
Advanced Hepatocellular Carcinoma
Sitravatinib
Carcinoma, Hepatocellular
LBL-007
Non-small Cell Lung Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Sorafenib | Phase 3 | Hepatocellular Carcinoma (HCC) | - | - |
Pamiparib capsule | Phase 3 | Ovarian Cancer | - | - |
Gemcitabine Hydrochloride | Phase 3 | Urothelial Carcinoma | - | - |
bendamustine | Phase 3 | Mantle Cell Lymphoma; Non-Hodgkin Lymphoma | - | - |
Docetaxel | Phase 3 | Non-small Cell Lung Cancer | - | - |
Sonrotoclax | Phase 3 | Chronic Lymphocytic Leukemia | - | - |
Cisplatin | Phase 3 | Esophageal Squamous Cell Carcinoma (ESCC) | - | - |
Irinotecan | Phase 3 | Esophageal Squamous Cell Carcinoma (ESCC) | - | - |
Gemcitabine | Phase 3 | Recurrent or Metastatic Nasopharyngeal Cancer | - | - |
Etoposide | Phase 3 | Small Cell Lung Cancer | - | - |
Ibrutinib | Phase 3 | Chronic Lymphocytic Leukemia | - | - |
Fluorouracil (5-FU) | Phase 3 | Esophageal Squamous Cell Carcinoma (ESCC) | - | - |
Lenalidomide | Phase 3 | Relapsed/Refractory Follicular Lymphoma | - | - |
Venetoclax | Phase 3 | Chronic Lymphocytic Leukemia | - | - |
Pembrolizumab | Phase 3 | Non-small Cell Lung Cancer | - | - |
Carboplatin | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Tislelizumab | Phase 3 | Urothelial Carcinoma | - | - |
Oxaliplatin | Phase 3 | Gastric, or Gastroesophageal Junction Adenocarcinoma | - | - |
Paclitaxel | Phase 3 | Non-Small Cell Lung Cancer | - | - |
BGB-3111 | Phase 3 | Waldenström's Macroglobulinemia | - | - |
Ociperlimab | Phase 3 | Limited Stage Small Cell Lung Cancer | - | - |
Cisplatin injection | Phase 3 | Non Small Cell Lung Cancer | - | - |
Obinutuzumab | Phase 3 | Relapsed/Refractory Follicular Non-Hodgkin Lymphoma | - | - |
BGB-16673 | Phase 3 | Chronic Lymphocytic Leukemia | - | - |
Zanubrutinib | Phase 3 | Refractory Mantle Cell Lymphoma | - | - |
5-fluorouracil | Phase 3 | Resectable Esophageal Squamous Cell Carcinoma | - | - |
Zanidatamab | Phase 2 | Breast Cancer | - | - |
Pemetrexed | Phase 2 | Non Small Cell Lung Cancer | - | - |
Capecitabine | Phase 2 | Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer | - | - |
Tislelizumab (BGB-A317) | Phase 2 | MSI-H/dMMR Solid Tumors | - | - |
BGB-10188 | Phase 2 | Chronic Lymphocytic Leukemia | - | - |
BGB-A445 | Phase 2 | Non-Small Cell Lung Cancer | - | - |
Azacitidine | Phase 2 | Acute Myeloid Leukemia | - | - |
BGB-A425 | Phase 2 | Locally Advanced or Metastatic Solid Tumors for Phase 1,Dose Escalation and Phase 2 Safety Lead-in, HNSCC, NSCLC and RCC Participants for Phase 2 | - | - |
lenvatinib | Phase 2 | Advanced Solid Tumor | - | - |
5-FU | Phase 2 | Esophageal Squamous Cell Carcinoma, Gastric Carcinoma, Gastroesophageal Junction Carcinoma | - | - |
Supportive Care | Phase 2 | COVID-19 Pulmonary Complications | - | - |
BGB-11417 | Phase 2 | Mantle Cell Lymphoma | - | - |
Chemotherapy Doublet | Phase 2 | Esophageal Cancer | - | - |
Fruquintinib | Phase 2 | Advanced Solid Tumors | - | - |
Pamiparib | Phase 2 | Brain and Central Nervous System Tumors | - | - |
Nab paclitaxel | Phase 2 | Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC) | - | - |
BGB-45035 | Phase 2 | Rheumatoid Arthritis | - | - |
BGB-DXP593 | Phase 2 | Covid19 | - | - |
BGB-290 | Phase 2 | HER2-negative Breast Cancer | - | - |
BAT1706 | Phase 2 | Advanced Hepatocellular Carcinoma | - | - |
Sitravatinib | Phase 2 | Carcinoma, Hepatocellular | - | - |
LBL-007 | Phase 2 | Non-small Cell Lung Cancer | - | - |